<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03042273</url>
  </required_header>
  <id_info>
    <org_study_id>PAC-001</org_study_id>
    <nct_id>NCT03042273</nct_id>
  </id_info>
  <brief_title>High Strength Cranberry Supplementation for Prevention of Recurrent Urinary Tract Infection</brief_title>
  <official_title>A Randomised, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of High Strength Cranberry (Pacran®) in Women With Recurrent Urinary Tract Infections (Cystitis)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swisse Wellness Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Commonwealth Scientific and Industrial Research Organisation, Australia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swisse Wellness Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is a Phase 2, multicenter, placebo-controlled, double-blind, parallel-arm
      study to evaluate the efficacy and safety of High Strength Cranberry (500mg Pacran®) in
      preventing UTI (cystitis) in women with a history of recurrent UTI (rUTI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of UTI</measure>
    <time_frame>6 months</time_frame>
    <description>cultured confirmed UTIs at a level of &gt;108cfu/L (105cfu/mL)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>High Strength Cranberry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 capsule of High Strength Cranberry (25,000mg Vaccinium macrocarpon) orally daily for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule of Matching Placebo orally daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High Strength Cranberry</intervention_name>
    <description>Softgel capsule</description>
    <arm_group_label>High Strength Cranberry</arm_group_label>
    <other_name>25,000mg Vaccinium macrocarpon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Soy oil to match High Strength Cranberry Softgel Capsule</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo (for High Strength Cranberry)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females aged 18-65 years, inclusive

          2. A history of recurrent urinary tract infection defined as ≥3 UTIs in the last year OR
             at least 2 UTIs occurring in the last 6 months. Each infection requires confirmation
             by a health professional and at least one infection confirmed by culture.

          3. Willing to answer questionnaires and comply with the study requirements

          4. Ability to swallow capsules

          5. Provided Written Informed Consent

          6. BMI &gt;17.5kg m2 and &lt;35kg m2

        Exclusion Criteria:

          1. Microbial growth on urine culture of ≥107 cfu/L (104cfu/mL) within 7 days of Day 1

          2. A history of &gt;5 UTIs in the last 6 months (confirmed by self-report or health
             professional)

          3. Use of antibiotics or antibiotics for prophylaxis within 28 days of Day 1

          4. Use of any antibacterial products, that in the opinion of the Medical Investigator may
             interfere with the study outcomes, within 28 days of Day 1

          5. Regular use of Vaccinium containing products (e.g. all forms of blueberries,
             cranberries, bilberry, lingonberry , etc i.e fruit, dried fruit, pills, juices or
             supplements) within 28 days of Day 1 at the discretion of the Medical Investigator

          6. Presence of an intermittent or indwelling urinary catheter

          7. Anatomical abnormalities of the urinary tract
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females with a history of recurrent UTIs</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Welma Stonehouse, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CSIRO</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bianca Benassi, PhD</last_name>
    <phone>+61 8 8303 8982</phone>
    <email>Bianca.Benassi@csiro.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Holdsworth House Medical Centre</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trina Vincent</last_name>
      <phone>02 8038 1044</phone>
      <email>Trina.Vincent@holdsworthhouse.com.au</email>
    </contact>
    <investigator>
      <last_name>Mark Bloch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holdsworth House Medical Centre</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trina Vincent</last_name>
      <phone>02 8038 1044</phone>
      <email>Trina.Vincent@holdsworthhouse.com.au</email>
    </contact>
    <investigator>
      <last_name>Fiona Bisshop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CSIRO Nutrition and Health Research Clinic</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Benassi-Evans, PhD</last_name>
      <phone>+61 8 83038982</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2017</study_first_submitted>
  <study_first_submitted_qc>February 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2017</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

